The stupid posts by fudfighter4 and the usual suspects belie reality and investor sentiment.
The results were disappointing is true- the trial met the primary endpoint of being not as good as TOBI - yippie!
The adverse affects were smoothed over by Will Lewis who did an exemplary job of speaking to Arikaces advantages for CF patients.( duration, but competitor TIP is cheaper,effective and approved)
Investors know that the regulatory pathway investor sentiment company finances were all lowered going forward,.CF in Europe in a couple of years is a minimal marketing victory imho- I predict it will not get first tier coverage in socialized medicine govt and drug coverage.
The risks are much higher now - dilution delays are just 2 possibilities that should give all caution.The clowns will post out of theirass to make themselves feel good. My ignore and trading will continue on Monday